Microfluidic preparation of chlorambucil nanoemulsion formulations and evaluation of cytotoxicity and pro-apoptotic activity in tumor cells

Journal of Biomedical Nanotechnology

Volumn 4, Issue 2, 2008, Pages 165-173

  Ganta, Srinivas ^a,c   Devalapally, Harikrishna ^a   Baguley, Bruce C ^b   Garg, Sanjay ^c   Amiji, Mansoor ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Apoptotic activity; Chlorambucil; Cytotoxicity; Microfluidizer ; Oil in water nanoemulsion; Ovarian adenocarcinoma cells

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; CHLORAMBUCIL; MACROGOL; SOYBEAN OIL;

APOPTOSIS; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; EMULSION; HUMAN; HUMAN CELL; NANOENCAPSULATION; OVARY ADENOCARCINOMA; PROCESS OPTIMIZATION; SOLID TUMOR; TUMOR CELL;

EID: 58149089908     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. S. Khandavilli and R. Panchagnula, Nanoemulsions as versatile formulations for paclitaxel delivery: peroral and dermal delivery studies in rats, J. Invest. Dermatol. 127, 154 (2007).
2. A. Kurihara, Y. Shibayama, A. Mizota, A. Yasuno, M. Ikeda, K. Sasagawa, T. Kobayashi, and M. Hisaoka, Enhanced tumor delivery and antitumor activity of palmitoyl rhizoxin using stable lipid emulsions in mice, Pharm. Res. 13, 305 (1996).
3. M. Masquelier, B. Lundberg, C. Peterson, and S. Vitols, Cytotoxic effect of a lipophilic alkylating agent after incorporation into low density lipoprotein or emulsions: studies in human leukemic cells, Leuk. Res. 30, 136 (2006).
4. R. R. Patlolla and V. Vobalaboina, Pharmacokinetics and tissue distribution of etoposide delivered in parenteral emulsion, J. Pharm. Sci. 94, 437 (2005).
5. D. K. Sarker, Engineering of nanoemulsions for drug delivery, Curr. Drug Deliv. 2, 297 (2005).
6. S. B. Tiwari and M. M. Amiji, Improved oral delivery of paclitaxel following administration in nanoemulsion formulations, J. Nanosci. Nanotechnol. 6, 3215 (2006).
7. A. Desai, T. Vyas, and M. Amiji, Cytotoxicity and apoptosis enhancement in brain tumor cells upon coadministration of paclitaxel and ceramide in nanoemulsion formulations, J. Pharm. Sci. (2007), in press.
8. T. K. Vyas, A. Shahiwala, and M. M. Amiji, Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations, Int. J. Pharm. 347, 93 (2007).
9. V. P. Torchilin, Multifunctional nanocarriers, Adv. Drug Deliv. Rev. 58, 1532 (2006).
10. J. Edmond, Essential polyunsaturated fatty acids and the barrier to the brain: the components of a model for transport, J. Mol. Neurosci. 16, 181; Discussion 215-121 (2001).
11. R. Kapoor and Y. S. Huang, Gamma linolenic acid: an antiinflammatory omega-6 fatty acid, Curr. Pharm. Biotechnol. 7, 531 (2006).
12. M. La Guardia, S. Giammanco, D. Di Majo, G. Tabacchi, E. Tripoli, and M. Giammanco, Omega 3 fatty acids: biological activity and effects on human health, Panminerva. Med. 47, 245 (2005).
13. S. B. Tiwari and M. M. Amiji, A review of nanocarrier-based CNS delivery systems, Curr. Drug Deliv. 3, 219 (2006).
14. V. Chajes and P. Bougnoux, Omega-6/omega-3 polyunsaturated fatty acid ratio and cancer, World Rev. Nutr. Diet. 92, 133 (2003).
15. D. P. Rose and J. M. Connolly, Omega-3 fatty acids as cancer chemopreventive agents, Pharmacol. Ther. 83, 217 (1999).
16. B. Lundberg, Preparation of drug-carrier emulsions stabilized with phosphatidylcholine-surfactant mixtures, J. Pharm. Sci. 83, 72 ( 1994).
17. J. L. Fink, 3rd, Application of the food and drug administration's current good manufacturing practices regulations to pharmacy practice: a legal view, Contemp. Pharm. Pract. 2, 202 (1979).
18. S. Pinnamaneni, N. G. Das, and S. K. Das, Comparison of oil-in-water emulsions manufactured by microfluidization and homogenization, Pharmazie. 58, 554 (2003).
19. D. F. Driscoll, Lipid injectable emulsions: 2006, Nutr. Clin. Pract. 21, 381 (2006).
20. D. L. Waitzberg, R. S. Torrinhas, and T. M. Jacintho, New parenteral lipid emulsions for clinical use, JPEN J. Parenter. Enteral. Nutr. 30, 351 (2006).
21. V. P. Torchilin, Liposomes as targetable drug carriers, Crit. Rev. Ther. Drug Carrier Syst. 2, 65 (1985).
22. V. P. Torchilin, Recent advances with liposomes as pharmaceutical carriers, Nat. Rev. Drug Discov. 4, 145 (2005).
23. F. Drablos, E. Feyzi, P. A. Aas, C. B. Vaagbo, B. Kavli, M. S. Bratlie, J. Pena-Diaz, M. Ottetlei, G. Slupphaug, and H. E. Krokan, Alkylation damage in DNA and RNA-repair mechanisms and medical significance, DNA Repair (Amst). 3, 1389 (2004).
24. A. G. Hall and M. J. Tilby, Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies, Blood Rev. 6, 163 (1992).
25. T. Robak, Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies, Transfus Apher. Sci. 32, 33 (2005).
26. J. Fang, T. Sawa, and H. Maeda, Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS, Adv. Exp. Med. Biol. 519, 29 (2003).
27. H. Maeda, The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting, Adv. Enzyme Regul. 41, 189 (2001).
28. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori, Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review, J. Control. Release. 65, 271 (2000).
29. G. Thurston, J. W. McLean, M. Rizen, P. Baluk, A. Haskell, T. J. Murphy, D. Hanahan, and D. M. McDonald, Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice, J. Clin. Invest. 101, 1401 (1998).
30. J. Rossi, S. Giasson, M. N. Khalid, P. Delmas, C. Allen, and J. C. Leroux, Long-circulating poly(ethylene glycol)-coated emulsions to target solid tumors, Eur. J. Pharm. Biopharm. 67, 329 (2007).
31. M. Schmitt-Sody, S. Strieth, S. Krasnici, B. Sauer, B. Schulze, M. Teifel, U. Michaelis, K. Naujoks, and M. Dellian, Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy, Clin. Cancer Res. 9, 2335 (2003).
32. K. J. Chandler, J. B. McCabe, and D. L. Kirkpatrick, High-performance liquid chromatographic method for the separation of chlorambucil and its N-oxide prodrug, J. Chromatogr. 652, 195 (1994).
33. H. Ehrsson, S. Eksborg, I. Wallin, and S. O. Nilsson, Degradation of chlorambucil in aqueous solution, J. Pharm. Sci. 69, 1091 (1980).
34. N. H. Greig, S. Genka, E. M. Daly, D. J. Sweeney, and S. I. Rapoport, Physicochemical and pharmacokinetic parameters of seven lipophilic chlorambucil esters designed for brain penetration, Cancer Chemother. Pharmacol. 25, 311 (1990).